The oral mucosa as a therapeutic target for xerostomia

Oral Diseases

Volumn 14, Issue 8, 2008, Pages 683-689

  Thelin, W R ^a   Brennan, M T ^b   Lockhart, P B ^b   Singh, M L ^c   Fox, P C ^b   Papas, A S ^c   Boucher, R C ^d  

^a Parion Sciences   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Absorption; Buccal mucosa; Dry mouth; ENaC; Epithelial sodium channel; Xerostomia

Indexed keywords

AMILORIDE; CEVIMELINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; PILOCARPINE; POTASSIUM; PS 55202; PS 5522; SALIVA SUBSTITUTE; SODIUM; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYSTIC FIBROSIS; ELECTROLYTE TRANSPORT; EVAPORATION; FLUID BALANCE; FLUID INTAKE; FLUSHING; HUMAN; HYDRATION; MOUTH MUCOSA; MOUTHWASH; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SALIVATION; SIDE EFFECT; SJOEGREN SYNDROME; SWEATING; URINARY FREQUENCY; WATER ABSORPTION; WATER PERMEABILITY; WATER TRANSPORT; XEROSTOMIA;

ABSORPTION; BODY WATER; HUMANS; ION TRANSPORT; MOUTH MUCOSA; SALIVA; SECRETORY RATE; WATER; WATER-ELECTROLYTE BALANCE; XEROSTOMIA;

EID: 54049146937     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2008.01486.x     Document Type: Review

References (52)

1. Aoyama W (1968). [The experimental study on the permeability of the oral mucosa with sodium-24 solution]. Shigaku 56 : 555 578.
2. Atkinson JC, Fox PC (1993). Sjogren's syndrome: oral and dental considerations. J Am Dent Assoc 124 : 74 76, 78-82, 84-86.
3. Becks H, Wainwright WW (1943). Human Saliva. XIII. Rate of flow of resting saliva of healthy individuals. J Dent Res 22 : 391 396.
4. Ben-Aryeh H, Miron D, Szargel R, Gutman D (1984). Whole-saliva secretion rates in old and young healthy subjects. J Dent Res 63 : 1147 1148.
5. Ben-Aryeh H, Miron D, Berdicevsky I, Szargel R, Gutman D (1985). Xerostomia in the elderly: prevalence, diagnosis, complications and treatment. Gerodontology 4 : 77 82.
6. Boucher RC (2007). Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 58 : 157 170.
7. Brennan MT, Lockhart PB, Boucher RC, Fox PC (2007). Mucosal fluid transport in healty volunteers. Oral Surg Oral Med Oral Pathol Oral Radiol Endo 103 : 787 788.
8. Collins LM, Dawes C (1987). The surface area of the adult human mouth and thickness of the salivary film covering the teeth and oral mucosa. J Dent Res 66 : 1300 1302.
9. Dawes C (1987). Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 66 : 648 653.
10. Dawes C (2004). How much saliva is enough for avoidance of xerostomia? Caries Res 38 : 236 240.
11. Dawes C, Odlum O (2004). Salivary status in patients treated for head and neck cancer. J Can Dent Assoc 70 : 397 400.
12. DiSabato-Mordarski T, Kleinberg I (1996a). Measurement and comparison of the residual saliva on various oral mucosal and dentition surfaces in humans. Arch Oral Biol 41 : 655 665.
13. DiSabato-Mordarski T, Kleinberg I (1996b). Use of a paper-strip absorption method to measure the depth and volume of saliva retained in embrasures and occlusal fussae of the human dentition. Arch Oral Biol 41 : 809 820.
14. Felszeghy S, Modis L, Nemeth P et al (2004). Expression of aquaporin isoforms during human and mouse tooth development. Arch Oral Biol 49 : 247 257.
15. Fox PC (2004). Salivary enhancement therapies. Caries Res 38 : 241 246.
16. Fox PC, Atkinson JC, Macynski AA et al (1991). Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 151 : 1149 1152.
17. Handelman SL, Baric JM, Saunders RH, Espeland MA (1989). Hyposalivatory drug use, whole stimulated salivary flow, and mouth dryness in older, long-term care residents. Spec Care Dentist 9 : 12 18.
18. Healy CM, Cruchley AT, Thornhill MH, Williams DM (2000). The effect of sodium lauryl sulphate, triclosan and zinc on the permeability of normal oral mucosa. Oral Dis 6 : 118 123.
19. Heintze U, Birkhed D, Bjorn H (1983). Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex. Swed Dent J 7 : 227 238.
20. Hirsh AJ, Zhang J, Zamurs A et al (2008). Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy) phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 325 : 77 88.
21. Horiot JC, Lipinski F, Schraub S et al (2000). Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 55 : 233 239.
22. Hosoya K, Kubo H, Natsume H, Sugibayashi K, Morimoto Y, Yamashita S (1993). The structural barrier of absorptive mucosae: site difference of the permeability of fluorescein isothiocyanate-labelled dextran in rabbits. Biopharm Drug Dispos 14 : 685 695.
23. Howie NM, Trigkas TK, Cruchley AT, Wertz PW, Squier CA, Williams DM (2001). Short-term exposure to alcohol increases the permeability of human oral mucosa. Oral Dis 7 : 349 354.
24. Johnson JT, Ferretti GA, Nethery WJ et al (1993). Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 329 : 390 395.
25. Kaaber S (1974). The permeability and barrier functions of the oral mucosa with respect to water and electrolytes. Studies of the transport of water, sodium and potassium through the human mucosal surface in vivo. Acta Odontol Scand Suppl 32 : 3 47.
26. Kawamura Y, Takata M (1960). Studies on the permeability of the oral mucosa. I. Permeability of inorganicions. J Dent Res 39 : 517 524.
27. Lagerlof F, Dawes C (1984). The volume of saliva in the mouth before and after swallowing. J Dent Res 63 : 618 621.
28. Lang L (2008). The Food and Drug Administration approves lubiprostone for irritable Bowel syndrome with constipation. Gastroenterology 135 : 7.
29. Lesch CA, Squier CA, Cruchley A, Williams DM, Speight P (1989). The permeability of human oral mucosa and skin to water. J Dent Res 68 : 1345 1349.
30. LeVeque FG, Montgomery M, Potter D et al (1993). A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 11 : 1124 1131.
31. Mackenzie IC, Binnie WH (1983). Recent advances in oral mucosal research. J Oral Pathol 12 : 389 415.
32. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC (2004). Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10 : 487 493.
33. Matsui H, Grubb BR, Tarran R et al (1998). Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95 : 1005 1015.
34. Matsuzaki T, Suzuki T, Koyama H, Tanaka S, Takata K (1999). Water channel protein AQP3 is present in epithelia exposed to the environment of possible water loss. J Histochem Cytochem 47 : 1275 1286.
35. Orlando RC, Tobey NA, Schreiner VJ, Readling RD (1988). Active electrolyte transport in mammalian buccal mucosa. Am J Physiol 255 : G286 G291.
36. Osterberg T, Birkhed D, Johansson C, Svanborg A (1992). Longitudinal study of stimulated whole saliva in an elderly population. Scand J Dent Res 100 : 340 345.
37. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P (2002). A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 46 : 748 754.
38. Scott J, Flower EA, Burns J (1987). A quantitative study of histological changes in the human parotid gland occurring with adult age. J Oral Pathol 16 : 505 510.
39. Selvaratnam L, Cruchley AT, Navsaria H et al (2001). Permeability barrier properties of oral keratinocyte cultures: a model of intact human oral mucosa. Oral Dis 7 : 252 258.
40. Ship JA, Fox PC, Baum BJ (1991). How much saliva is enough? 'Normal' function defined. J Am Dent Assoc 122 : 63 69.
41. Ship JA, Pillemer SR, Baum BJ (2002). Xerostomia and the geriatric patient. J Am Geriatr Soc 50 : 535 543.
42. Siegal IA (1984). The Structure and Function of the Oral Mucosa. Pergamon : Oxford, UK.
43. Singh ML, Papas AS, Fox PC et al (2008). Use of sodium channel blocker to relieve dryness in Sjögren's (Abstract No. 0553). J Dent Res 87 (Special Issue A 101150.
44. Talal N (1987). Overview of Sjogren's syndrome. J Dent Res 66 (Special No. 672 674.
45. Tarran R, Grubb BR, Parsons D et al (2001). The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 8 : 149 158.
46. Tarran R, Donaldson S, Boucher RC (2007). Rationale for hypertonic saline therapy for cystic fibrosis lung disease. Semin Respir Crit Care Med 28 : 295 302.
47. Tauber J, Davitt WF, Bokosky JE et al (2004). Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 23 : 784 792.
48. Thelin WR, Boucher RC (2007). The epithelium as a target for therapy in cystic fibrosis. Curr Opin Pharmacol 7 : 290 295.
49. Turner MD, Ship JA (2007). Dry mouth and its effects on the oral health of elderly people. J Am Dent Assoc 138 (Suppl. 15S 20S.
50. Vivino FB, Al-Hashimi I, Khan Z et al (1999). Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 159 : 174 181.
51. Wolff M, Kleinberg I (1998). Oral mucosal wetness in hypo- and normosalivators. Arch Oral Biol 43 : 455 462.
52. Wolff MS, Kleinberg I (1999). The effect of ammonium glycopyrrolate (Robinul)-induced xerostomia on oral mucosal wetness and flow of gingival crevicular fluid in humans. Arch Oral Biol 44 : 97 102.